815 related articles for article (PubMed ID: 16467546)
1. NXY-059 for acute ischemic stroke.
Lees KR; Zivin JA; Ashwood T; Davalos A; Davis SM; Diener HC; Grotta J; Lyden P; Shuaib A; Hårdemark HG; Wasiewski WW;
N Engl J Med; 2006 Feb; 354(6):588-600. PubMed ID: 16467546
[TBL] [Abstract][Full Text] [Related]
2. NXY-059 for the treatment of acute ischemic stroke.
Shuaib A; Lees KR; Lyden P; Grotta J; Davalos A; Davis SM; Diener HC; Ashwood T; Wasiewski WW; Emeribe U;
N Engl J Med; 2007 Aug; 357(6):562-71. PubMed ID: 17687131
[TBL] [Abstract][Full Text] [Related]
3. Effects of tissue plasminogen activator for acute ischemic stroke at one year. National Institute of Neurological Disorders and Stroke Recombinant Tissue Plasminogen Activator Stroke Study Group.
Kwiatkowski TG; Libman RB; Frankel M; Tilley BC; Morgenstern LB; Lu M; Broderick JP; Lewandowski CA; Marler JR; Levine SR; Brott T
N Engl J Med; 1999 Jun; 340(23):1781-7. PubMed ID: 10362821
[TBL] [Abstract][Full Text] [Related]
4. NXY-059 for the treatment of acute stroke: pooled analysis of the SAINT I and II Trials.
Diener HC; Lees KR; Lyden P; Grotta J; Davalos A; Davis SM; Shuaib A; Ashwood T; Wasiewski W; Alderfer V; Hårdemark HG; Rodichok L;
Stroke; 2008 Jun; 39(6):1751-8. PubMed ID: 18369171
[TBL] [Abstract][Full Text] [Related]
5. NXY-059: review of neuroprotective potential for acute stroke.
Fong JJ; Rhoney DH
Ann Pharmacother; 2006 Mar; 40(3):461-71. PubMed ID: 16507608
[TBL] [Abstract][Full Text] [Related]
6. Additional outcomes and subgroup analyses of NXY-059 for acute ischemic stroke in the SAINT I trial.
Lees KR; Davalos A; Davis SM; Diener HC; Grotta J; Lyden P; Shuaib A; Ashwood T; Hardemark HG; Wasiewski W; Emeribe U; Zivin JA;
Stroke; 2006 Dec; 37(12):2970-8. PubMed ID: 17068304
[TBL] [Abstract][Full Text] [Related]
7. Effect of intravenous tirofiban and aspirin in reducing short-term and long-term neurologic deficit in patients with ischemic stroke: a double-blind randomized trial.
Torgano G; Zecca B; Monzani V; Maestroni A; Rossi P; Cazzaniga M; Manganaro D; Boiti C; Zilioli E; Borutti G; Falaschi F; Mandelli C
Cerebrovasc Dis; 2010 Feb; 29(3):275-81. PubMed ID: 20090319
[TBL] [Abstract][Full Text] [Related]
8. Comparison of combined venous and arterial thrombolysis with primary arterial therapy using recombinant tissue plasminogen activator in acute ischemic stroke.
Wolfe T; Suarez JI; Tarr RW; Welter E; Landis D; Sunshine JL; Zaidat OO
J Stroke Cerebrovasc Dis; 2008; 17(3):121-8. PubMed ID: 18436152
[TBL] [Abstract][Full Text] [Related]
9. Recombinant tissue plasminogen activator for minor strokes: the National Institute of Neurological Disorders and Stroke rt-PA Stroke Study experience.
National Institute of Neurological Disorders Stroke rt-PA Stroke Study Group
Ann Emerg Med; 2005 Sep; 46(3):243-52. PubMed ID: 16126134
[TBL] [Abstract][Full Text] [Related]
10. Older age does not increase risk of hemorrhagic complications after intravenous and/or intra-arterial thrombolysis for acute stroke.
Pundik S; McWilliams-Dunnigan L; Blackham KL; Kirchner HL; Sundararajan S; Sunshine JL; Tarr RW; Selman WR; Landis DM; Suarez JI
J Stroke Cerebrovasc Dis; 2008 Sep; 17(5):266-72. PubMed ID: 18755405
[TBL] [Abstract][Full Text] [Related]
11. Effect of Alteplase vs Aspirin on Functional Outcome for Patients With Acute Ischemic Stroke and Minor Nondisabling Neurologic Deficits: The PRISMS Randomized Clinical Trial.
Khatri P; Kleindorfer DO; Devlin T; Sawyer RN; Starr M; Mejilla J; Broderick J; Chatterjee A; Jauch EC; Levine SR; Romano JG; Saver JL; Vagal A; Purdon B; Devenport J; Pavlov A; Yeatts SD;
JAMA; 2018 Jul; 320(2):156-166. PubMed ID: 29998337
[TBL] [Abstract][Full Text] [Related]
12. Stroke treatment with alteplase given 3.0-4.5 h after onset of acute ischaemic stroke (ECASS III): additional outcomes and subgroup analysis of a randomised controlled trial.
Bluhmki E; Chamorro A; Dávalos A; Machnig T; Sauce C; Wahlgren N; Wardlaw J; Hacke W
Lancet Neurol; 2009 Dec; 8(12):1095-102. PubMed ID: 19850525
[TBL] [Abstract][Full Text] [Related]
13. Renal impairment reduces the efficacy of thrombolytic therapy in acute ischemic stroke.
Power A; Epstein D; Cohen D; Bathula R; Devine J; Kar A; Taube D; Duncan N; Ames D
Cerebrovasc Dis; 2013; 35(1):45-52. PubMed ID: 23428996
[TBL] [Abstract][Full Text] [Related]
14. NXY-059 for acute ischemic stroke: the promise of neuroprotection is finally realized?
Fisher M
Stroke; 2006 Oct; 37(10):2651-2. PubMed ID: 16946143
[No Abstract] [Full Text] [Related]
15. Statin use and functional outcome after tissue plasminogen activator treatment in acute ischaemic stroke.
Miedema I; Uyttenboogaart M; Koopman K; De Keyser J; Luijckx GJ
Cerebrovasc Dis; 2010 Feb; 29(3):263-7. PubMed ID: 20090317
[TBL] [Abstract][Full Text] [Related]
16. Coadministration of NXY-059 and tenecteplase six hours following embolic strokes in rabbits improves clinical rating scores.
Lapchak PA; Song D; Wei J; Zivin JA
Exp Neurol; 2004 Aug; 188(2):279-85. PubMed ID: 15246827
[TBL] [Abstract][Full Text] [Related]
17. Long-term outcome as function of blood pressure in acute ischemic stroke and effects of thrombolysis.
Yong M; Diener HC; Kaste M; Mau J
Cerebrovasc Dis; 2007; 24(4):349-54. PubMed ID: 17690547
[TBL] [Abstract][Full Text] [Related]
18. [Intravenous thrombolytic treatment in acute ischemic stroke: initial results in the Complejo Hospitalario Universitario de Albacete].
García-García J; Gracia-Gil J; Sopelana-Garay D; Ayo-Martín O; Vadillo-Bermejo A; Touza B; Peñalver-Pardines C; Zorita MD; Segura T
Rev Neurol; 2008 Jan 1-15; 46(1):7-12. PubMed ID: 18214820
[TBL] [Abstract][Full Text] [Related]
19. Does mild deficit for patients with stroke justify the use of intravenous tissue plasminogen activator?
Hassan AE; Zacharatos H; Hassanzadeh B; El-Gengaihy A; AlKawi A; Shhadeh A; Kirmani JF
J Stroke Cerebrovasc Dis; 2010 Mar; 19(2):116-20. PubMed ID: 20189087
[TBL] [Abstract][Full Text] [Related]
20. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke.
Hacke W; Kaste M; Bluhmki E; Brozman M; Dávalos A; Guidetti D; Larrue V; Lees KR; Medeghri Z; Machnig T; Schneider D; von Kummer R; Wahlgren N; Toni D;
N Engl J Med; 2008 Sep; 359(13):1317-29. PubMed ID: 18815396
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
